Merus to Participate in Citi’s 13th Annual Biotech Conference
UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at Citi’s 13th Annual Biotech Conference entitled, “Landscape in Immuno-Oncology and Bi-Specific Antibodies” on Thursday, September 6, 2018, at 9:00 a.m. ET.
A live webcast of the panel will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus’ website, www.merus.nl.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases26.9.2018 14:00 | Pressemelding
Broad European Patent Issued Supports XBiotech’s Skin Disease Program for Monoclonal Antibody Bermekimab AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization p
CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models26.9.2018 14:00 | Pressemelding
Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft (PDX) models of prostate cancer. Prostate cancer is the second most common cancer in males, impacting more than 1 million new patients worldwide each year. The disease has long been underrepresented at the preclinical modeling stage of drug development, due to the difficulty in establishing PDX models. CrownBio is committed to providing clinically relevant solutions for diseases with high unmet need. PDX are the most translatable preclinical models currently available, directly derived from patient tissue and reflectin
OTP Bank Selects eGain’s Knowledge Management for Customer Service26.9.2018 12:30 | Pressemelding
eGain’s AI and knowledge management solution will be deployed at the bank’s contact centres and retail branches with the support of eGain partner Pattern Digital Consulting SUNNYVALE, Calif. and NEWBURY, United Kingdom, Sept. 26, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of cloud-based customer engagement solutions today announced that OTP Bank, one of the largest banks serving Central and Eastern Europe, has selected eGain for omnichannel customer service. Pattern Digital Consulting Ltd., an implementation partner for eGain, will work with eGain Quick Value Services™ team to deploy eGain’s award-winning solution for AI-infused knowledge to provide conversational, procedural, and process guidance to agents at the bank’s contact centers and retail branches. The bank tried out eGain’s solution as part of eGain Try+Buy™ consumption model, which is a risk-free production pilot with no obligation to buy and no-charge guidance for success. Happy with the agent exper
Canadian Natural Resources Limited Announces Completion of the Extension Period to Acquire All Issued and Outstanding Shares of Laricina Energy Ltd.26.9.2018 11:00 | Pressemelding
CALGARY, Alberta, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited (“Canadian Natural" or the "Company") announces that Canadian Natural's offer to acquire all of the issued and outstanding common shares (the “Laricina Shares") of Laricina Energy Ltd. (“Laricina”) for $0.0815 per Laricina Share by way of a take-over bid (the "Offer"), as extended on September 13, 2018 for the mandatory 10-day extension period, expired at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018. Since Canadian Natural's initial take up of 568,724,430 Laricina Shares on September 13, 2018, Computershare Investor Services Inc., the depositary, has reported that as at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018, an additional 3,594,872 Laricina Shares (the "Additional Shares") were validly deposited under the Offer and not withdrawn. Canadian Natural has taken up and accepted for payment all such Additional Shares and payment for such Additional Shares will be made as so
Juniper Systems Unveils New Cedar CP3 Rugged Smartphone26.9.2018 06:36 | Pressemelding
BIRMINGHAM, United Kingdom, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Systems Limited today announced the release of its newest Cedar™ device, the Cedar CP3™ Rugged Smartphone. The rugged smartphone arrives two years after its predecessor, the CT5™ Rugged Smartphone, bringing massive upgrades to nearly every specification. The CP3 touts battery life of 14-16 hours operating at full brightness and while running GPS. The CP3 is powered by a Snapdragon 653 octa-core processor, delivering fast load times and top-tier performance for advanced tasks without draining the battery. ‘Rugged doesn’t have to mean bulky and slow’, said Simon Bowe, general manager of Juniper Systems Limited. ‘The CP3 proves that smartphones can be purpose-built for data collection in the world’s toughest environments – and are also handy for surfing online at home’. The Cedar CP3 Rugged Smartphone is available globally and works on any GSM network. The powerful battery delivers a shocking 480-hour standby time and
Tenaris to acquire significant stake in Saudi Steel Pipe Company25.9.2018 22:58 | Pressemelding
LUXEMBOURG, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it has entered into a definitive agreement to acquire from a private group 47.79% of the shares of Saudi Steel Pipe Company (“SSP”), a welded steel pipes producer listed on the Saudi stock market, for an aggregate price of US$144 million. The transaction is subject to regulatory approvals, including approval by the Capital Market Authority of Saudi Arabia, and other customary conditions and is expected to close in the first quarter of 2019. Tenaris has been serving Saudi Arabia’s oil and gas industry and Saudi Aramco for decades. With this transaction, Tenaris will significantly expand its industrial presence in the Kingdom and the range of products it supplies to Saudi Aramco. Since its first industrial investment in 2010, Tenaris has continuously invested to expand its local operations, supporting the industrialization of the country. SSP’s facilitie
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom